# John H. Stone

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/john-h-stone/

## Facts

| Field | Value |
| --- | --- |
| Citations | 51,672 |
| Field | Vasculitis and related conditions |
| h-index | 97 |
| i10-index | 307 |
| Last Known Institution | Massachusetts General Hospital |
| OpenAlex ID | https://openalex.org/A5042482253 |
| ORCID iD | https://orcid.org/0000-0001-6588-9435 |
| Works | 645 |

## Researcher papers

Showing 12 of 16.

- [2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides](https://scholariq.org/papers/2012-revised-international-chapel-hill-consensus-conference-nomenclature-of-2/)
- [Consensus statement on the pathology of IgG4-related disease](https://scholariq.org/papers/consensus-statement-on-the-pathology-of-igg4-related-disease/)
- [Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I](https://scholariq.org/papers/estimates-of-the-prevalence-of-arthritis-and-other-rheumatic-conditions-in-the-2/)
- [Efficacy of Tocilizumab in Patients Hospitalized with Covid-19](https://scholariq.org/papers/efficacy-of-tocilizumab-in-patients-hospitalized-with-covid-19/)
- [Trial of Tocilizumab in Giant-Cell Arteritis](https://scholariq.org/papers/trial-of-tocilizumab-in-giant-cell-arteritis/)
- [International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease](https://scholariq.org/papers/international-consensus-guidance-statement-on-the-management-and-treatment-of/)
- [Recommendations for the nomenclature of IgG4‐related disease and its individual organ system manifestations](https://scholariq.org/papers/recommendations-for-the-nomenclature-of-igg4-related-disease-and-its-individual/)
- [Rituximab for IgG4-related disease: a prospective, open-label trial](https://scholariq.org/papers/rituximab-for-igg4-related-disease-a-prospective-open-label-trial/)
- [The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4‐Related Disease](https://scholariq.org/papers/the-2019-american-college-of-rheumatology-european-league-against-rheumatism-2/)
- [IgG4‐Related Disease: Clinical and Laboratory Features in One Hundred Twenty‐Five Patients](https://scholariq.org/papers/igg4-related-disease-clinical-and-laboratory-features-in-one-hundred-twenty-five/)
- [A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritis](https://scholariq.org/papers/a-multicenter-randomized-double-blind-placebo-controlled-trial-of-adjuvant/)
- [Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations](https://scholariq.org/papers/plasmablasts-as-a-biomarker-for-igg4-related-disease-independent-of-serum-igg4/)

## Researcher topics

- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions-2/)
- [IgG4-Related and Inflammatory Diseases](https://scholariq.org/topics/igg4-related-and-inflammatory-diseases/)
- [Otitis Media and Relapsing Polychondritis](https://scholariq.org/topics/otitis-media-and-relapsing-polychondritis/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Gastrointestinal disorders and treatments](https://scholariq.org/topics/gastrointestinal-disorders-and-treatments/)

## Researcher university

- [Massachusetts General Hospital](https://scholariq.org/institutions/massachusetts-general-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.